CRON Fundamental Analysis - CRONOS GROUP INC

Fundamental Rating

We assign a fundamental rating of 5 out of 10 to CRON. CRON was compared to 195 industry peers in the Pharmaceuticals industry. While CRON has a great health rating, there are worries on its profitability. CRON is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

CRON had positive earnings in the past year.

CRON had a positive operating cash flow in the past year.

CRON had negative earnings in 4 of the past 5 years.

In the past 5 years CRON reported 4 times negative operating cash flow.

1.2 Ratios

The Return On Assets of CRON (4.29%) is better than 87.69% of its industry peers.

CRON has a Return On Equity of 4.64%. This is amongst the best in the industry. CRON outperforms 84.62% of its industry peers.

		Industry Rank	Sector Rank
ROA	4.29%
ROE	4.64%
ROIC	N/A

ROA(3y)-5.62%

ROA(5y)-9.8%

ROE(3y)-5.87%

ROE(5y)-10.3%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Profit Margin, with a value of 39.68%, CRON belongs to the top of the industry, outperforming 97.95% of the companies in the same industry.

CRON's Profit Margin has declined in the last couple of years.

The Gross Margin of CRON (27.65%) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	39.68%
GM	27.65%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5Y-62.81%

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

CRON does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for CRON has been increased compared to 1 year ago.

The number of shares outstanding for CRON has been increased compared to 5 years ago.

CRON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

CRON has an Altman-Z score of 6.50. This indicates that CRON is financially healthy and has little risk of bankruptcy at the moment.

With an excellent Altman-Z score value of 6.50, CRON belongs to the best of the industry, outperforming 83.59% of the companies in the same industry.

CRON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	6.5

ROIC/WACCN/A

WACC8.57%

2.3 Liquidity

A Current Ratio of 27.80 indicates that CRON has no problem at all paying its short term obligations.

Looking at the Current ratio, with a value of 27.80, CRON belongs to the top of the industry, outperforming 96.41% of the companies in the same industry.

CRON has a Quick Ratio of 26.75. This indicates that CRON is financially healthy and has no problem in meeting its short term obligations.

Looking at the Quick ratio, with a value of 26.75, CRON belongs to the top of the industry, outperforming 95.90% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	27.8
Quick Ratio	26.75

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 285.71% over the past year.

The earnings per share for CRON have been decreasing by -50.78% on average. This is quite bad

The Revenue has grown by 33.92% in the past year. This is a very strong growth!

CRON shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 37.71% yearly.

EPS 1Y (TTM)285.71%

EPS 3YN/A

EPS 5Y-50.78%

EPS Q2Q%300%

Revenue 1Y (TTM)33.92%

Revenue growth 3Y16.47%

Revenue growth 5Y37.71%

Sales Q2Q%27.58%

3.2 Future

CRON is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -21.14% yearly.

Based on estimates for the next years, CRON will show a small growth in Revenue. The Revenue will grow by 1.87% on average per year.

EPS Next Y-144.2%

EPS Next 2Y-9.67%

EPS Next 3Y-39.52%

EPS Next 5Y-21.14%

Revenue Next Year18.44%

Revenue Next 2Y12.81%

Revenue Next 3Y7.09%

Revenue Next 5Y1.87%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 14.69, which indicates a correct valuation of CRON.

85.64% of the companies in the same industry are more expensive than CRON, based on the Price/Earnings ratio.

Compared to an average S&P500 Price/Earnings ratio of 26.34, CRON is valued a bit cheaper.

The Price/Forward Earnings ratio is 23.41, which indicates a rather expensive current valuation of CRON.

CRON's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. CRON is cheaper than 71.28% of the companies in the same industry.

CRON's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 22.19.

		Industry Rank	Sector Rank
PE	14.69
Fwd PE	23.41

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as CRON's earnings are expected to decrease with -39.52% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-9.67%

EPS Next 3Y-39.52%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for CRON!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CRONOS GROUP INC

NASDAQ:CRON (6/18/2025, 8:00:00 PM)

After market: 1.91 0 (0%)

1.91

0 (0%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)05-08 2025-05-08/bmo

Earnings (Next)08-06 2025-08-06

Inst Owners13.12%

Inst Owner Change1.35%

Ins Owners6.2%

Ins Owner Change12.24%

Market Cap736.13M

Analysts76

Price Target1.74 (-8.9%)

Short Float %1.65%

Short Ratio1.73

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)0

Avg Revenue beat(2)-7.6%

Min Revenue beat(2)-14.99%

Max Revenue beat(2)-0.21%

Revenue beat(4)2

Avg Revenue beat(4)-0.3%

Min Revenue beat(4)-14.99%

Max Revenue beat(4)9.73%

Revenue beat(8)4

Avg Revenue beat(8)0.25%

Revenue beat(12)4

Avg Revenue beat(12)-4.65%

Revenue beat(16)7

Avg Revenue beat(16)-2.62%

PT rev (1m)-34.8%

PT rev (3m)-31.64%

EPS NQ rev (1m)100%

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)-749.62%

Revenue NQ rev (1m)-5.74%

Revenue NQ rev (3m)-11.14%

Revenue NY rev (1m)0%

Revenue NY rev (3m)2.63%

Valuation

		Industry Rank	Sector Rank
PE	14.69
Fwd PE	23.41
P/S	5.91
P/FCF	N/A
P/OCF	38.84
P/B	0.69
P/tB	0.74
EV/EBITDA	N/A

EPS(TTM)0.13

EY6.81%

EPS(NY)0.08

Fwd EY4.27%

FCF(TTM)-0.02

FCFYN/A

OCF(TTM)0.05

OCFY2.57%

SpS0.32

BVpS2.77

TBVpS2.58

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	4.29%
ROE	4.64%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	39.68%
GM	27.65%
FCFM	N/A

ROA(3y)-5.62%

ROA(5y)-9.8%

ROE(3y)-5.87%

ROE(5y)-10.3%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5Y-62.81%

GM growth 3YN/A

GM growth 5YN/A

F-Score6

Asset Turnover0.11

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	253.86%
Cap/Sales	21.28%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	27.8
Quick Ratio	26.75
Altman-Z	6.5

F-Score6

WACC8.57%

ROIC/WACCN/A

Cap/Depr(3y)70.04%

Cap/Depr(5y)158.35%

Cap/Sales(3y)6.62%

Cap/Sales(5y)22.42%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)285.71%

EPS 3YN/A

EPS 5Y-50.78%

EPS Q2Q%300%

EPS Next Y-144.2%

EPS Next 2Y-9.67%

EPS Next 3Y-39.52%

EPS Next 5Y-21.14%

Revenue 1Y (TTM)33.92%

Revenue growth 3Y16.47%

Revenue growth 5Y37.71%

Sales Q2Q%27.58%

Revenue Next Year18.44%

Revenue Next 2Y12.81%

Revenue Next 3Y7.09%

Revenue Next 5Y1.87%

EBIT growth 1Y32.67%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year98.02%

EBIT Next 3Y27.54%

EBIT Next 5Y9.95%

FCF growth 1Y92.98%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y118.45%

OCF growth 3YN/A

OCF growth 5YN/A

CRONOS GROUP INC (CRON) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens